Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Oct;62(4):561–566. doi: 10.1038/bjc.1990.330

Modification of tumour radiation response in vivo by the benzamide analogue pyrazinamide.

D J Chaplin 1, M J Trotter 1, K A Skov 1, M R Horsman 1
PMCID: PMC1971487  PMID: 2145963

Abstract

Pyrazinamide, the pyrazine analogue of nicotinamide, has been evaluated for its ability to modify the radiation response of hypoxic cells both in vivo and in vitro. Results obtained with three different murine tumour systems EMT6, LLC and SCCVII showed that pyrazinamide at a dose of 0.5 mg g-1 i.p. resulted in enhanced radiation response. Dose modification factors of between 1.3 and 1.6 were observed using in vivo/in vitro clonogenic assays. This enhancement was greater than that obtained in mouse intestine using crypt cell survival as an endpoint (DMF 1.1). In contrast to the tumour data in vivo, the in vitro results indicate that pyrazinamide displays little radiosensitising or toxic properties towards hypoxic CHO cells in culture. These results suggest that pyrazinamide exerts its effects in vivo either by directly perturbing tumour physiology or by being converted to an active metabolite. Blood flow studies performed using laser Doppler flowmetry indicate that pyrazinamide produces a small (32%) increase in overall tumour blood flow in the SCCVII tumour. Based on this finding, additional studies on tumour perfusion at the microregional level were performed in the SCCVII tumour using a histological technique involving injection of fluorescent stains which demarcate functional vasculature. The data show that when compared to saline injected controls, pyrazinamide reduced the number of vessels opening and closing over a 20 min period from 10.2% to 3.8%. This finding suggests that pyrazinamide may exert its effects at least in part by reducing the occurrence of acute hypoxia resulting from dynamic changes in microregional perfusion.

Full text

PDF
561

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams G. E., Clarke E. D., Flockhart I. R., Jacobs R. S., Sehmi D. S., Stratford I. J., Wardman P., Watts M. E., Parrick J., Wallace R. G. Structure-activity relationships in the development of hypoxic cell radiosensitizers. I. Sensitization efficiency. Int J Radiat Biol Relat Stud Phys Chem Med. 1979 Feb;35(2):133–150. doi: 10.1080/09553007914550151. [DOI] [PubMed] [Google Scholar]
  2. Adams G. E., Dische S., Fowler J. F., Thomlinson R. H. Hypoxic cell sensitisers in radiotherapy. Lancet. 1976 Jan 24;1(7952):186–188. doi: 10.1016/s0140-6736(76)91285-x. [DOI] [PubMed] [Google Scholar]
  3. Adams G. E. Radiosensitizers: a conference preview. Int J Radiat Oncol Biol Phys. 1984 Aug;10(8):1181–1184. doi: 10.1016/0360-3016(84)90314-6. [DOI] [PubMed] [Google Scholar]
  4. Barendsen G. W., Koot C. J., Van Kersen G. R., Bewley D. K., Field S. B., Parnell C. J. The effect of oxygen on impairment of the proliferative capacity of human cells in culture by ionizing radiations of different LET. Int J Radiat Biol Relat Stud Phys Chem Med. 1966;10(4):317–327. doi: 10.1080/09553006614550421. [DOI] [PubMed] [Google Scholar]
  5. Brown J. M. Keynote address: hypoxic cell radiosensitizers: where next? Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):987–993. doi: 10.1016/0360-3016(89)90901-2. [DOI] [PubMed] [Google Scholar]
  6. Brown J. M., Workman P. Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res. 1980 Apr;82(1):171–190. [PubMed] [Google Scholar]
  7. Chaplin D. J., Durand R. E., Olive P. L. Acute hypoxia in tumors: implications for modifiers of radiation effects. Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1279–1282. doi: 10.1016/0360-3016(86)90153-7. [DOI] [PubMed] [Google Scholar]
  8. Chaplin D. J., Horsman M. R., Trotter M. J. Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumor. J Natl Cancer Inst. 1990 Apr 18;82(8):672–676. doi: 10.1093/jnci/82.8.672. [DOI] [PubMed] [Google Scholar]
  9. Chaplin D. J., Olive P. L., Durand R. E. Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res. 1987 Jan 15;47(2):597–601. [PubMed] [Google Scholar]
  10. Chaplin D. J., Sheldon P. W., Stratford I. J., Ahmed I., Adams G. E. Radiosensitization in vivo: a study with an homologous series of 2-nitroimidazoles. Int J Radiat Biol Relat Stud Phys Chem Med. 1983 Oct;44(4):387–398. doi: 10.1080/09553008314551331. [DOI] [PubMed] [Google Scholar]
  11. Coleman C. N. Hypoxia in tumors: a paradigm for the approach to biochemical and physiologic heterogeneity. J Natl Cancer Inst. 1988 May 4;80(5):310–317. doi: 10.1093/jnci/80.5.310. [DOI] [PubMed] [Google Scholar]
  12. Courtenay V. D. A soft agar colony assay for Lewis lung tumour and B16 melanoma taken directly from the mouse. Br J Cancer. 1976 Jul;34(1):39–45. doi: 10.1038/bjc.1976.119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Dische S. Keynote address: hypoxic cell sensitizers: clinical developments. Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):1057–1060. doi: 10.1016/0360-3016(89)90915-2. [DOI] [PubMed] [Google Scholar]
  14. Franko A. J., Sutherland R. M. Radiation survival of cells from spheroids grown in different oxygen concentrations. Radiat Res. 1979 Sep;79(3):454–467. [PubMed] [Google Scholar]
  15. Henk J. M., Kunkler P. B., Smith C. W. Radiotherapy and hyperbaric oxygen in head and neck cancer. Final report of first controlled clinical trial. Lancet. 1977 Jul 16;2(8029):101–103. doi: 10.1016/s0140-6736(77)90116-7. [DOI] [PubMed] [Google Scholar]
  16. Hirst D. G. Oxygen delivery to tumors. Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1271–1277. doi: 10.1016/0360-3016(86)90152-5. [DOI] [PubMed] [Google Scholar]
  17. Hirst D. G., Wood P. J. Altered radiosensitivity in a mouse carcinoma after administration of clofibrate and bezafibrate. Radiother Oncol. 1989 May;15(1):55–61. doi: 10.1016/0167-8140(89)90118-7. [DOI] [PubMed] [Google Scholar]
  18. Horsman M. R., Brown D. M., Lemmon M. J., Brown J. M., Lee W. W. Preferential tumor radiosensitization by analogs of nicotinamide and benzamide. Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1307–1310. doi: 10.1016/0360-3016(86)90160-4. [DOI] [PubMed] [Google Scholar]
  19. Horsman M. R., Brown J. M., Hirst V. K., Lemmon M. J., Wood P. J., Dunphy E. P., Overgaard J. Mechanism of action of the selective tumor radiosensitizer nicotinamide. Int J Radiat Oncol Biol Phys. 1988 Sep;15(3):685–690. doi: 10.1016/0360-3016(88)90312-4. [DOI] [PubMed] [Google Scholar]
  20. Horsman M. R., Chaplin D. J., Brown J. M. Radiosensitization by nicotinamide in vivo: a greater enhancement of tumor damage compared to that of normal tissues. Radiat Res. 1987 Mar;109(3):479–489. [PubMed] [Google Scholar]
  21. Horsman M. R., Chaplin D. J., Brown J. M. Tumor radiosensitization by nicotinamide: a result of improved perfusion and oxygenation. Radiat Res. 1989 Apr;118(1):139–150. [PubMed] [Google Scholar]
  22. Horsman M. R., Evans J. W., Brown J. M. Enhancement of melphalan-induced tumour cell killing by misonidazole: an interaction of competing mechanisms. Br J Cancer. 1984 Sep;50(3):305–316. doi: 10.1038/bjc.1984.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Moore B. A., Palcic B., Skarsgard L. D. Radiosensitizing and toxic effects on the 2-nitroimidazole Ro-07-0582 in hypoxic mammation cells. Radiat Res. 1976 Sep;67(3):459–473. [PubMed] [Google Scholar]
  24. Olive P. L., Chaplin D. J., Durand R. E. Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours. Br J Cancer. 1985 Nov;52(5):739–746. doi: 10.1038/bjc.1985.252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Rockwell S. C., Kallman R. F., Fajardo L. F. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J Natl Cancer Inst. 1972 Sep;49(3):735–749. [PubMed] [Google Scholar]
  26. Sheldon P. W., Hill S. A. Hypoxic cell radiosensitizers and local control by X-ray of a transplanted tumour in mice. Br J Cancer. 1977 Jun;35(6):795–808. doi: 10.1038/bjc.1977.121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Shepherd A. P., Riedel G. L., Kiel J. W., Haumschild D. J., Maxwell L. C. Evaluation of an infrared laser-Doppler blood flowmeter. Am J Physiol. 1987 Jun;252(6 Pt 1):G832–G839. doi: 10.1152/ajpgi.1987.252.6.G832. [DOI] [PubMed] [Google Scholar]
  28. THOMLINSON R. H., GRAY L. H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955 Dec;9(4):539–549. doi: 10.1038/bjc.1955.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Teicher B. A., Rose C. M. Oxygen-carrying perfluorochemical emulsion as an adjuvant to radiation therapy in mice. Cancer Res. 1984 Oct;44(10):4285–4288. [PubMed] [Google Scholar]
  30. Trotter M. J., Acker B. D., Chaplin D. J. Histological evidence for nonperfused vasculature in a murine tumor following hydralazine administration. Int J Radiat Oncol Biol Phys. 1989 Oct;17(4):785–789. doi: 10.1016/0360-3016(89)90067-9. [DOI] [PubMed] [Google Scholar]
  31. Trotter M. J., Chaplin D. J., Durand R. E., Olive P. L. The use of fluorescent probes to identify regions of transient perfusion in murine tumors. Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):931–934. doi: 10.1016/0360-3016(89)90889-4. [DOI] [PubMed] [Google Scholar]
  32. Trotter M. J., Chaplin D. J., Olive P. L. Use of a carbocyanine dye as a marker of functional vasculature in murine tumours. Br J Cancer. 1989 May;59(5):706–709. doi: 10.1038/bjc.1989.148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Withers H. R., Elkind M. M. Microcolony survival assay for cells of mouse intestinal mucosa exposed to radiation. Int J Radiat Biol Relat Stud Phys Chem Med. 1970;17(3):261–267. doi: 10.1080/09553007014550291. [DOI] [PubMed] [Google Scholar]
  34. Zwi L. J., Baguley B. C., Gavin J. B., Wilson W. R. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J Natl Cancer Inst. 1989 Jul 5;81(13):1005–1013. doi: 10.1093/jnci/81.13.1005. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES